20/20 BioLabs Sees Q2 MCED Revenue Jump 30%+, Targets Medicare Coverage by 2028
AIDX sits 19% above its 52-week low of $0.511 on light trading volume (0.3× avg).
Summary
The company guided for its highest-ever quarterly MCED revenue in Q2, at least 30% above the prior-year period, signaling accelerating adoption of its OneTest™ cancer screening platform. This follows a challenging Q1 that saw revenue decline and heavy dilution, making the growth inflection notable. The webinar detailed a path toward potential Medicare reimbursement beginning in 2028 under new federal legislation, though FDA authorization and CMS approval remain uncertain. Real-world data from over 35,000 firefighter screenings by year-end could strengthen the regulatory case. The company also highlighted its M&A strategy targeting health and wellness firms, adding a potential inorganic growth lever.
At the time of this announcement, AIDX was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.51 to $50.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.